| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $441,060 ) |
| | 2024 | 2024 | SYNTR HEALTH TECHNOLOGIES, INC. | 5270 CALIFORNIA AVE STE 300 | IRVINE | CA | 92617-3231 | ORANGE | USA | R43TR004975 | Device Automation of an FDA-cleared CD-Microfluidic Platform for Rapid Tissue Microsizing | 001 | 1 | NIH | 7/10/2024 | $134,899 |
| | 2024 | 2024 | SYNTR HEALTH TECHNOLOGIES, INC. | 5270 CALIFORNIA AVE STE 300 | IRVINE | CA | 92617-3231 | ORANGE | USA | R43TR004975 | Device Automation of an FDA-cleared CD-Microfluidic Platform for Rapid Tissue Microsizing | 000 | 1 | NIH | 12/8/2023 | $306,161 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2017 | SYNTR HEALTH TECHNOLOGIES, LLC | 18806 SOUTH PRADO CT | CERRITOS | CA | 90703-5909 | LOS ANGELES | USA | R43DK116389 | Mechanical Activation of Adipose-Derived Stem Cells for the Treatment of Diabetic Foot Ulcers Using a Novel CD-Microfluidic Device | 000 | 1 | NIH | 1/6/2020 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $300,000 ) |
| | 2017 | 2017 | SYNTR HEALTH TECHNOLOGIES, LLC | 18806 SOUTH PRADO CT | CERRITOS | CA | 90703-5909 | LOS ANGELES | USA | R43DK116389 | Mechanical Activation of Adipose-Derived Stem Cells for the Treatment of Diabetic Foot Ulcers Using a Novel CD-Microfluidic Device | 000 | 1 | NIH | 9/13/2017 | $300,000 |
|
|
